MedCity News August 30, 2023
Despite these wins for many patients, the new law is already impacting the discovery and development of new drugs for people living with orphan diseases. Not only are drugs that could treat more than one disease being disincentivized, small molecule medicines, which play an important role in treating neurological disorders, cancers, and other diseases, may also be disadvantaged by the law.
The Inflation Reduction Act was created and passed to reduce patient and government burden in paying for expensive drugs. While the new legislation is intended to provide Medicare patients with better access to the treatments they need, certain provisions have the effect of penalizing research and driving companies away from developing specific types of drugs—in particular, potential treatments for...